DE69942525D1 - Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff - Google Patents

Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff

Info

Publication number
DE69942525D1
DE69942525D1 DE69942525T DE69942525T DE69942525D1 DE 69942525 D1 DE69942525 D1 DE 69942525D1 DE 69942525 T DE69942525 T DE 69942525T DE 69942525 T DE69942525 T DE 69942525T DE 69942525 D1 DE69942525 D1 DE 69942525D1
Authority
DE
Germany
Prior art keywords
defective
replication
flaviviruses
present
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942525T
Other languages
English (en)
Inventor
Lingling Zeng
Lewis Markoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Government filed Critical US Government
Application granted granted Critical
Publication of DE69942525D1 publication Critical patent/DE69942525D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69942525T 1998-09-02 1999-02-05 Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff Expired - Lifetime DE69942525D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9898198P 1998-09-02 1998-09-02
PCT/US1999/002598 WO2000014245A1 (en) 1998-09-02 1999-02-05 Dengue viruses that are replication defective in mosquitos for use as vaccines

Publications (1)

Publication Number Publication Date
DE69942525D1 true DE69942525D1 (de) 2010-08-05

Family

ID=22271837

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942525T Expired - Lifetime DE69942525D1 (de) 1998-09-02 1999-02-05 Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff

Country Status (6)

Country Link
EP (1) EP1108036B1 (de)
AT (1) ATE471983T1 (de)
AU (1) AU774045B2 (de)
CA (1) CA2341354C (de)
DE (1) DE69942525D1 (de)
WO (1) WO2000014245A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
JP2005510244A (ja) * 2001-11-26 2005-04-21 ザ・ユニヴァーシティ・オヴ・クイーンズランド フラビウイルスワクチン送達系
US7851194B2 (en) * 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
EP1879921B1 (de) 2005-05-12 2011-04-27 Crucell Holland B.V. Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
JP5538729B2 (ja) 2006-02-27 2014-07-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 偽感染性フラビウイルスおよびそれらの使用
CN105246506A (zh) 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
CN106999568A (zh) 2014-12-22 2017-08-01 默沙东公司 登革病毒疫苗组合物及其使用方法
CN108697785B (zh) * 2015-12-23 2022-08-02 瓦尔尼瓦奥地利有限责任公司 Zika病毒疫苗
CA3015792A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872553B1 (de) * 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimäre und/oder wachstumgehemmte Flaviviren

Also Published As

Publication number Publication date
WO2000014245A1 (en) 2000-03-16
AU2661099A (en) 2000-03-27
CA2341354C (en) 2009-10-20
EP1108036B1 (de) 2010-06-23
EP1108036A1 (de) 2001-06-20
CA2341354A1 (en) 2000-03-16
ATE471983T1 (de) 2010-07-15
AU774045B2 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
DE69942525D1 (de) Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
ATE229978T1 (de) Helicobacter proteine und impstoffe
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
HK1046016B (zh) 疫苗中的重組脫氧核糖核酸膠原
ATE328068T1 (de) Papillomavirus vakzine
EA200401507A1 (ru) Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
NZ547776A (en) Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein
SI1554301T1 (sl) VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
BR9807873A (pt) Vacinas de flavivìrus quiméricos
NO20000850L (no) Vaksine
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
LU91151I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétaniqud, d'anatoxine coquelucheuse, d'hémagglutine filamenteuse, de pertactine, d'antigène de surf ace recombinant de virus de l'hépatite B (protéineS), e virus poliomyélitique inactivé type 1, type3et de polyoside d'Haemophilus influenzae type b.
ATE366582T1 (de) Optimierte minigene und dadurch kodierte peptide
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
PT789590E (pt) Imunopotenciacao induzida por quitosano
DE59712852D1 (de) Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
PT712926E (pt) Virus da doenca pancreatica do peixe
DE69124215D1 (de) Primaten-lentivirus impfstoffe
IL168374A (en) Vaccines against west nile virus
DE60129358D1 (de) Genetische immunisierung gegen zervixkarzinom
HUP0303902A2 (hu) Interleukin-18-indukáló anyag
AU5573196A (en) A pluripotent vaccine against enveloped viruses
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2004067032A3 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes